JP2012524771A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524771A5
JP2012524771A5 JP2012506583A JP2012506583A JP2012524771A5 JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5 JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5
Authority
JP
Japan
Prior art keywords
oil
eur
composition
composition according
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524771A (ja
Filing date
Publication date
Priority claimed from GB0906977A external-priority patent/GB2469792A/en
Priority claimed from PCT/GB2009/050416 external-priority patent/WO2010122276A1/en
Application filed filed Critical
Priority claimed from PCT/GB2010/050671 external-priority patent/WO2010122355A1/en
Publication of JP2012524771A publication Critical patent/JP2012524771A/ja
Publication of JP2012524771A5 publication Critical patent/JP2012524771A5/ja
Pending legal-status Critical Current

Links

JP2012506583A 2009-04-23 2010-04-23 中性油を含む舌下用の医薬組成物 Pending JP2012524771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0906977.4 2009-04-23
GB0906977A GB2469792A (en) 2009-04-23 2009-04-23 Oil-based pharmaceutical formulation for sublingual delivery
GBPCT/GB2009/050416 2009-04-23
PCT/GB2009/050416 WO2010122276A1 (en) 2009-04-23 2009-04-23 Drug delivery
PCT/GB2010/050671 WO2010122355A1 (en) 2009-04-23 2010-04-23 Sublingual pharmaceutical composition comprising a neutral oil

Publications (2)

Publication Number Publication Date
JP2012524771A JP2012524771A (ja) 2012-10-18
JP2012524771A5 true JP2012524771A5 (https=) 2013-05-09

Family

ID=42236683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506583A Pending JP2012524771A (ja) 2009-04-23 2010-04-23 中性油を含む舌下用の医薬組成物

Country Status (15)

Country Link
US (1) US20120058158A1 (https=)
EP (1) EP2421503A1 (https=)
JP (1) JP2012524771A (https=)
CN (1) CN102458358A (https=)
AU (1) AU2010240653A1 (https=)
BR (1) BRPI1013539A2 (https=)
CA (1) CA2756879A1 (https=)
IL (1) IL215454A (https=)
MX (1) MX2011010835A (https=)
MY (1) MY167918A (https=)
NZ (1) NZ595467A (https=)
RU (1) RU2011139638A (https=)
SG (1) SG175160A1 (https=)
WO (1) WO2010122355A1 (https=)
ZA (1) ZA201107089B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US20130254139A1 (en) * 2012-03-21 2013-09-26 Xiaoguang Lei Systems and methods for building a universal intelligent assistant with learning capabilities
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10376586B2 (en) * 2016-02-16 2019-08-13 Entourage Bioscience, LLC Method and compositions for solubilizing non-polar constituents
WO2017192921A1 (en) * 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) * 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
EP3558279A4 (en) * 2016-12-26 2020-12-02 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN
KR20200060748A (ko) * 2017-09-27 2020-06-01 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 및 프로드러그 조성물
WO2020136620A1 (en) 2018-12-29 2020-07-02 3M Innovative Properties Company Oral articles and methods of use
CN113271909A (zh) 2018-12-29 2021-08-17 3M创新有限公司 口腔制品及使用方法
CA3178140A1 (en) 2020-03-31 2021-10-07 Nomoreitis B.V. Treatment of hyperinflammatory syndrome
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63503304A (ja) * 1986-03-10 1988-12-02 ブルグハルト,クルト 医薬製剤およびその製造方法
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
ES2535233T3 (es) * 2006-01-25 2015-05-06 Insys Therapeutics, Inc. Pulverización de fentanilo sublingual
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
SI2424523T1 (sl) * 2009-04-23 2012-11-30 Londonpharma Ltd Podjezična aerosolna formulacija ki vsebuje dihidroartemezinin

Similar Documents

Publication Publication Date Title
JP2012524771A5 (https=)
RU2011139638A (ru) Сублингвальная фармацевтическая композиция, содержащая нейтральное масло
JP7250865B2 (ja) 固溶体組成物および心血管疾患における使用
JP2022174168A (ja) ω3脂肪酸の自己乳化組成物
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
JP2013508296A5 (https=)
JP2014509655A5 (https=)
KR20160032120A (ko) ω3 지방산의 자기 유화 조성물
Aggarwal et al. Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation
JP2015520236A5 (https=)
RU2014139008A (ru) Гормонсодержащая эмульсия, содержащая фосфолипиды криля
WO2009139589A3 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
WO2002039983A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
RU2017111503A (ru) КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2008120711A1 (ja) タミバロテンカプセル剤
RU2015102597A (ru) Липидные композиции рацекадотрила
Goswami et al. Permeation enhancer for TDDS from natural and synthetic sources: A review
GB2469754A (en) Sub-lingual drug delivery system using a neutral oil
CA2829015C (en) Formulation comprising phenylaminopyrimidine derivative as active agent
AR084235A1 (es) Composiciones farmaceuticas que comprenden alisporivir
HK1199396A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
RU2011127248A (ru) Экструдаты с игловидными действующими веществами
JP2012524772A (ja) ジヒドロアルテミシニンを含む舌下スプレー用製剤
JP2016514706A5 (https=)
RU2013121269A (ru) Фармацевтическая композиция и применение фосфолипида в такой фармацевтической композиции